At the Forefront of the Fight Against Pancreatic Cancer

At this year’s GI meeting, more than 30 Celgene-related abstracts underscore the fact that Celgene is the leader in pancreatic cancer research.

Pancreatic cancer is once again an area of focus at this year’s 2016 Gastrointestinal Cancers Symposium in San Francisco. More than 3,000 attendees are gathering from January 21 to 23 to discuss the latest advances in pancreatic cancer and other GI cancers. Nearly one in 10 abstracts accepted for the meeting—more than ever before—addresses pancreatic cancer. This is significant and increasingly important as the mortality rate could surpass that of breast and colorectal cancers by 2030 in some countries. Celgene is at the forefront of the fight against pancreatic cancer, and at this year’s GI meeting there are more than 30 Celgene-related abstracts that underscore the fact that Celgene is both the leader in pancreatic cancer research and the partner of choice for organizations with emerging investigational treatments.

GI2016: Over 70 posters and presentations associated with pancreatic cancer treatment. More than 40 involve investigational uses of Celgene products.

Celgene continues the fight against pancreatic cancer through our commitment in advancing research, our collaboration with advocacy groups and our support to patients.

Some look. We envision.

Celgene: Your partner in the fight against pancreatic cancer.

Celgene is committed to advancing research to help change the lives of patients with pancreatic cancer. In 2015, more than 30 percent of our revenue was reinvested into R&D, one of the highest rates in the industry.

Part of our research aims to inform today’s treatment choices in pancreatic cancer. Given the availability of more treatment options for patients with metastatic pancreatic adenocarcinoma, it is time to develop a treatment plan for patients. Celgene is contributing to this important discussion by helping physicians and patients make informed treatment decisions. With an eye toward the future, we are also conducting research and collaborating with researchers around the world on 47 ongoing investigational trials that combine novel agents with the foundation of approved Celgene therapies. These trials involve more than 40 unique novel compounds across more than 30 mechanisms of action and target enrollment of more than 4,500 pancreas cancer patients.

 In recent year, Celgene has committed nearly 30 percent of revenue to research.

Some hear. We listen.

Celgene collaborates with patient advocacy groups to bring hope to the fight against pancreatic cancer. Together with 29 international patient groups, Celgene created the first-ever World Pancreatic Cancer Day in 2014 and continues to grow the event. Celgene also supports events such as Purple Stride Walks in the United States, the European Multi-Stakeholder platform on Pancreatic Cancer in November 2014, 2015 Pancreatic Cancer Forum in Milan and grants to help transport patients to their treatment appointments through the CancerCare GetYouThere program.

Some touch. We feel.

Celgene is dedicated to offering compassion and support to patients with pancreatic cancer and those who care for them. To help them, Celgene developed, a personal pancreatic cancer information center. The site provides information about the disease, clinical trials, support groups, finances and communication and allows patients and caregivers to create their own online libraries of relevant information. Celgene also recognizes that pancreatic cancer patients often have special nutritional needs due to compromised pancreatic function. Our response: a source for recipes and meal planning. Lastly, we are committed to increasing the awareness of pancreatic cancer in the healthcare community.

Pancreatic Cancer: Cooking. Comfort. Care.

Supporting all who fight pancreatic cancer.

At ASCO GI, Celgene will be hosting social media discussions of pancreatic cancer and appreciating those active in the fight against it. Under the theme of “Your Partner In The Fight Against Pancreatic Cancer,” Celgene will be driving discussion around this critical disease across a range of social channels.

To learn more: